Literature DB >> 30293556

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease.

Jordi Guardiola1, Triana Lobatón2, Elena Cerrillo3, Rocío Ferreiro-Iglesias4, Javier P Gisbert5, Eugeni Domènech2, María Chaparro5, Maria Esteve6, Francisco Rodríguez-Moranta7.   

Abstract

The management of inflammatory bowel disease (IBD) is currently based on the objective evaluation of intestinal lesions. It would therefore be interesting to have access to simple and non-invasive tools to monitor IBD activity and to identify the presence of lesions. Faecal calprotectin (FC) is the main cytosolic protein of neutrophils, it is resistant to bacterial degradation and it is stable at room temperature for several days, characteristics that make it suitable for use in clinical practice. It can be used to differentiate between inflammatory and functional processes, it correlates with endoscopic activity, it is associated with clinical and endoscopic response to treatment and it has short-term prognostic value. This paper offers an up-to-date perspective on the information that FC can provide clinicians to aid diagnosis, monitoring and management of IBD.
Copyright © 2018 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Calprotectin; Calprotectina; Colitis ulcerosa; Crohn's disease; Endoscopic remission; Enfermedad de Crohn; Histological remission; Postsurgical recurrence; Recurrencia posquirúrgica; Remisión endoscópica; Remisión histológica; Ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 30293556     DOI: 10.1016/j.gastrohep.2018.05.029

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  5 in total

1.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

2.  Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.

Authors:  Marleen Bouhuys; Willem S Lexmond; Gerard Dijkstra; Triana Lobatón; Edouard Louis; Stephanie van Biervliet; Henk Groen; Jordi Guardiola; Patrick van Rheenen
Journal:  BMJ Open       Date:  2021-11-03       Impact factor: 2.692

3.  State-of-the-art surgery for ulcerative colitis.

Authors:  Shanglei Liu; Samuel Eisenstein
Journal:  Langenbecks Arch Surg       Date:  2021-08-28       Impact factor: 3.445

Review 4.  Diagnosis and natural history of preclinical and early inflammatory bowel disease.

Authors:  Iago Rodríguez-Lago; Yamile Zabana; Manuel Barreiro-de Acosta
Journal:  Ann Gastroenterol       Date:  2020-06-22

5.  A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients.

Authors:  Gonzalo Hijos-Mallada; Raul Velamazán; Raúl Marti; Eduardo Chueca; Samantha Arechavaleta; Alberto Lué; Fernando Gomollón; Angel Lanas; Carlos Sostres
Journal:  Diagnostics (Basel)       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.